skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Accelerated Partial Breast Irradiation for Pure Ductal Carcinoma in Situ

Abstract

Purpose: To report outcomes for ductal carcinoma in situ (DCIS) treated with breast-conserving therapy using accelerated partial breast irradiation (APBI). Methods and Materials: From March 2001 to February 2009, 53 patients with Stage 0 breast cancer were treated with breast conserving surgery and adjuvant APBI. Median age was 62 years. All patients underwent excision with margins negative by {>=}1 mm before adjuvant radiotherapy (RT). A total of 39 MammoSite brachytherapy (MS) patients and 14 three-dimensional conformal external beam RT (3DCRT) patients were treated to the lumpectomy bed alone with 34 Gy and 38.5 Gy, respectively. Of the DCIS cases, 94% were mammographically detected. All patients with calcifications had either specimen radiography or postsurgical mammography confirmation of clearance. Median tumor size was 6 mm, and median margin distance was 5 mm. There were no statistically significant differences according to APBI method for race/ethnicity, tumor detection method, tumor grade, estrogen receptor (ER) status, or use of tamoxifen (p = NS). Recurrence and survival were calculated using the Kaplan-Meier method. Cosmesis was scored by the Harvard criteria. Results: With a median follow-up of 3.6 years (range, 0.4-6.3 years), the overall and cause-specific survival rates were 98% and 100%, respectively. Three-year actuarial ipsilateral breastmore » tumor recurrence was 2%. One failure was observed at the resection bed 11 months post-RT. No other elsewhere breast failures, regional recurrences, or distant metastases were noted. Cosmesis was excellent or good in 92.4% of cases, with no statistically significant differences according to the APBI method (92.3% with MammoSite and 92.8% with 3DCRT; p = 0.649). Conclusions: APBI as part of breast-conserving therapy for pure DCIS was associated with excellent local control and survival rates, with the vast majority of patients having good to excellent cosmesis. This finding supports the recent analysis by the American Society of Breast Surgeons on a subset of DCIS patients treated efficaciously with APBI.« less

Authors:
; ; ; ; ; ;  [1];  [1]
  1. Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI (United States)
Publication Date:
OSTI Identifier:
21587748
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 81; Journal Issue: 2; Other Information: DOI: 10.1016/j.ijrobp.2010.05.030; PII: S0360-3016(10)00753-4; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOMEDICAL RADIOGRAPHY; BRACHYTHERAPY; CARCINOMAS; ESTROGENS; IRRADIATION; MAMMARY GLANDS; METASTASES; RECEPTORS; SURGERY; TAMOXIFEN; BODY; DIAGNOSTIC TECHNIQUES; DISEASES; GLANDS; HORMONES; MEDICINE; MEMBRANE PROTEINS; NEOPLASMS; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANS; PROTEINS; RADIOLOGY; RADIOTHERAPY; STEROID HORMONES; THERAPY

Citation Formats

Park, Sean S., Grills, Inga Siiner, Chen, Peter Y., Kestin, Larry L., Ghilezan, Michel I., Wallace, Michelle, Martinez, Alvaro M., and Vicini, Frank A., E-mail: fvicini@beaumont.edu. Accelerated Partial Breast Irradiation for Pure Ductal Carcinoma in Situ. United States: N. p., 2011. Web. doi:10.1016/j.ijrobp.2010.05.030.
Park, Sean S., Grills, Inga Siiner, Chen, Peter Y., Kestin, Larry L., Ghilezan, Michel I., Wallace, Michelle, Martinez, Alvaro M., & Vicini, Frank A., E-mail: fvicini@beaumont.edu. Accelerated Partial Breast Irradiation for Pure Ductal Carcinoma in Situ. United States. doi:10.1016/j.ijrobp.2010.05.030.
Park, Sean S., Grills, Inga Siiner, Chen, Peter Y., Kestin, Larry L., Ghilezan, Michel I., Wallace, Michelle, Martinez, Alvaro M., and Vicini, Frank A., E-mail: fvicini@beaumont.edu. Sat . "Accelerated Partial Breast Irradiation for Pure Ductal Carcinoma in Situ". United States. doi:10.1016/j.ijrobp.2010.05.030.
@article{osti_21587748,
title = {Accelerated Partial Breast Irradiation for Pure Ductal Carcinoma in Situ},
author = {Park, Sean S. and Grills, Inga Siiner and Chen, Peter Y. and Kestin, Larry L. and Ghilezan, Michel I. and Wallace, Michelle and Martinez, Alvaro M. and Vicini, Frank A., E-mail: fvicini@beaumont.edu},
abstractNote = {Purpose: To report outcomes for ductal carcinoma in situ (DCIS) treated with breast-conserving therapy using accelerated partial breast irradiation (APBI). Methods and Materials: From March 2001 to February 2009, 53 patients with Stage 0 breast cancer were treated with breast conserving surgery and adjuvant APBI. Median age was 62 years. All patients underwent excision with margins negative by {>=}1 mm before adjuvant radiotherapy (RT). A total of 39 MammoSite brachytherapy (MS) patients and 14 three-dimensional conformal external beam RT (3DCRT) patients were treated to the lumpectomy bed alone with 34 Gy and 38.5 Gy, respectively. Of the DCIS cases, 94% were mammographically detected. All patients with calcifications had either specimen radiography or postsurgical mammography confirmation of clearance. Median tumor size was 6 mm, and median margin distance was 5 mm. There were no statistically significant differences according to APBI method for race/ethnicity, tumor detection method, tumor grade, estrogen receptor (ER) status, or use of tamoxifen (p = NS). Recurrence and survival were calculated using the Kaplan-Meier method. Cosmesis was scored by the Harvard criteria. Results: With a median follow-up of 3.6 years (range, 0.4-6.3 years), the overall and cause-specific survival rates were 98% and 100%, respectively. Three-year actuarial ipsilateral breast tumor recurrence was 2%. One failure was observed at the resection bed 11 months post-RT. No other elsewhere breast failures, regional recurrences, or distant metastases were noted. Cosmesis was excellent or good in 92.4% of cases, with no statistically significant differences according to the APBI method (92.3% with MammoSite and 92.8% with 3DCRT; p = 0.649). Conclusions: APBI as part of breast-conserving therapy for pure DCIS was associated with excellent local control and survival rates, with the vast majority of patients having good to excellent cosmesis. This finding supports the recent analysis by the American Society of Breast Surgeons on a subset of DCIS patients treated efficaciously with APBI.},
doi = {10.1016/j.ijrobp.2010.05.030},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 2,
volume = 81,
place = {United States},
year = {2011},
month = {10}
}